Volume 1 Issue 2
Abnormalities of Fibrinolytic Parameters in Tunisian Patients with Behçet’s Disease. Correlations with the Clinical Presentation, the Activity, and the Severity of the Disease
Smiti Khanfir Monia*, Belfeki Nabil, Baccouche Hela, Said Fatma, Mahjoub Sonia, Hamzaoui Amira, Ben Romdhane Neila, Houman Mohamed Habib
Behçet’s disease (BD) is a chronic multisystemic inflammatory disorder characterized by recurrent oral and genital ulcers, uveitis, and skin lesions. BD can affect nearly all systems and organs, including the vascular system, central nervous system, gastrointestinal tract, lungs, kidneys, and joints. Venous thrombosis is frequent in BD, and particularly high in Tunisia, with 33% of patients reported by Houman et al. The pathogenesis of thrombosis in BD is not clear. Endothelial damage and/or defects in coagulation or fibrinolysis are thought to take a part.
A Dermatomyositis Patient Developing Chronic Myeloid Leukemia is able to Experience Improvement in the Quality of Daily Life, Following Treatment with Imatinib Mesylate
Kiyomitsu Miyachi*, Raleigh W. Hankins, Isei Koga, Shoichi Ozaki, Yasushi Shibuya, Ikuo Miura
A female patient was originally diagnosed with dermatomyositis in 1985 at the age of 56 because of the presence of interstitial pneumonia and skin lesions. Early in 2008, she experienced a high fever for one week, and essential thrombocytosis was suspected. However, G-banding analysis revealed reciprocal translocation between chromosomes 9 and 22 [t(9;22) (q34;q11.2)] . She was diagnosed with chronic myelogenous leukemia. Daily administration of 400mg of imatinib mesylate was started on April 1, 2008, and the patient’s WBC and thrombocyte counts had dropped from 11,200/μl to 5,500/μl and from 1,491,000/μl to 168,000/μl, respectively, by the end of April.
Tumor Lysis Syndrome Occurring During Treatment of Macrophage Activation Syndrome
Mohammed Al Pakra, Gihan Mahmoud, Tayseer Ahmed, Ehab Hanafy Ramadan*
Macrophage Activation Syndrome (MAC) is a form of Hemophagocytic lymphohistiocytosis (HLH) in patients with juvenile idiopathic arthritis and other rheumatologic conditions. Complication of treatment develop in various forms, however Tumor lysis syndrome is a very rare complication, which may occur during treatment of MAC. We herein present a rare case of MAC secondary to Systemic juvenile idiopathic arthritis, which was complicated by Tumor lysis syndrome at the initiation of treatment and was managed successfully.
Letter to the Editor
Hemophilia A Induced by Omalizumab
Luis Alberto Guardado Sánchez*, Alba Redondo Guijo, Santiago Santa Cruz Ruiz, José Ramón González Porras
Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment option for patients with moderate to severe allergic asthma whose condition is poorly controlled by inhaled corticosteroids and inhaled long-acting ß2-agonist bronchodilators. The most common side effects of omalizumab treatment are bruising, erythema and pain at the site of injection.However, the most serious adverse effect of omalizumab is anaphylaxis, although this occurs infrequently.